Approval · Notice of Compliance 7349 · 2005
RIVA-SUMATRIPTAN: Notice of Compliance 7349
Issued September 2, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7349
- Date
- September 2, 2005
- Company
- Laboratoire Riva Inc.Blainville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIVA-SUMATRIPTAN | 02271109 | Cancelled Pre Market |
| RIVA-SUMATRIPTAN | 02271117 | Cancelled Post Market |
| RIVA-SUMATRIPTAN | 02271125 | Cancelled Post Market |
Medicinal ingredients
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB